Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open, Randomized, Two-way Cross-over Phase I Study to Compare the Bioavailability, Safety and Tolerability of Single s.c. Doses of 300 IU XM17 With 300 IU Gonal-f® in 36 Healthy, Down-regulated Young Women

NCT02592031 is registered in ClinicalTrials.gov with Merckle GmbH as lead sponsor.

NCT NCT02592031
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02592031 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open, Randomized, Two-way Cross-over Phase I Study to Compare the Bioavailability, Safety and Tolerability of Single s.c. Doses of 300 IU XM17 With 300 IU Gonal-f® in 36 Healthy, Down-regulated Young Women
Lead sponsor
Merckle GmbH
Phase
Phase 1
Overall status
Completed
Start date
February 28, 2009
Completion date
December 31, 2009
Enrollment
49 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

bioequivalence